DS Stage I Plasma Cell Myeloma

10 clinical trials · Condition

Record	Firm	Date
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT01936090)	Mayo Clinic	2013-08-01
Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT01842308)	Mayo Clinic	2013-06-04
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma (NCT01668719)	SWOG Cancer Research Network	2012-11-01
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma (NCT01605032)	Albert Einstein College of Medicine	2012-02-01
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma (NCT01330173)	National Cancer Institute (NCI)	2010-12-01
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement (NCT00869206)	Alliance for Clinical Trials in Oncology	2009-03-01
Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant (NCT00839956)	Fred Hutchinson Cancer Center	2009-02-01
Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma (NCT00445692)	Fred Hutchinson Cancer Center	2007-01-10
Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma (NCT00088855)	National Cancer Institute (NCI)	2004-06-15

Track DS Stage I Plasma Cell Myeloma automatically

Every clearance here is in the API, with alerts when new ones post.